AHCL

Anlon Healthcare share price & results

Anlon Healthcare Limited· Healthcare

Rajkot-based manufacturer of pharmaceutical intermediates and APIs (Loxoprofen, Ketoprofen, Dexketoprofen) for pain/inflammation, with CDMO custom manufacturing and nutraceutical products sold across 15 countries.

₹25.56 −0.81%
MCap ₹1.4k Cr Price to earnings (TTM to Sept 2026) 41.00× Return on equity (TTM to Sept 2026) 13.62%

Free account: unlock 50 concall reads/mo, 5 full guidance ledgers, and same-day AHCL alerts.

Results to: Sept 2026 Latest analysed call: Q2 FY27 Ownership as of: Sept 2026
AHCL at a glance Plain-English snapshot from filed results & analysed earnings calls

Guidance Track Record

Management guidance vs. actual results

0 of 6 judged targets kept · 18 open · verdicts reflect calls analysed to Q2 FY27.

Anlon Healthcare Limited management guidance track record on Inve: 24 targets tracked across analysed earnings calls (0 achieved, 6 missed, 18 open).

Watch execution in Operations & Margins (1 delayed/missed).

TargetOriginal wordingSaidLatest callVerdict
Operations Net Debt
by third quarter of next financial year, we will be the debt-free. No bank loan for new expansion.
Q2 FY26
Q2 FY27:Reconfirmed planning term loan of INR 65-70 CR from banks to fund ongoing capex, solidifying the complete reversal of the debt-free target.
Missed
Growth FY27 Revenue
minimum 360 to 400 CR after inorganic acquisition
Q2 FY26
Q2 FY27:Raised bottom end of guidance back to INR 380-400 CR (up from INR 350-400 CR in Q1 FY27), supported by H1 FY27 revenue of INR 193.17 CR.
Revised Up
Growth Revenue Growth
30% plus revenue CAGR over the next three years
Q2 FY26
Q2 FY27:H1 FY27 revenue grew 125.9% YoY to INR 193.17 CR, and guided full-year FY27 (INR 380-400 CR) and FY28 (INR 650-700 CR) keep the 30%+ CAGR trajectory comfortably on track.
On Track

Source: Inve Guidance Tracker for Anlon Healthcare Limited · to Q2 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of Anlon Healthcare Limited's 24 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 21 more targets are in the full ledger.

Get the Inve app for Android on Google Play Get the Inve app for Android on Google Play Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Latest analysed call · Q2 FY27 · 3 Nov 2026

Q2 FY27: Anlon Healthcare Limited Q2 FY27

Anlon Healthcare demonstrated strong operational growth in Q2 FY27, with consolidated revenue doubling YoY to ₹105.61 crores and H1 FY27 performance exceeding the full-year FY26 topline. EBITDA margins rebounded sharply to 23.9% from 17.8% in Q1 FY27, driven by successful price revisions to absorb elevated raw material costs. The company is actively executing a ₹130 crore greenfield expansion at Rajkot to add 1,200 MTPA capacity by Q1 FY28, while expanding into finished dosages, biologics, and medical devices.

What management highlighted

  • Revenue from operations grew 102.3% YoY to ₹105.61 crores in Q2 FY27 and 125.9% YoY to ₹193.17 crores in H1 FY27
  • EBITDA margin expanded sequentially by over 600 bps from 17.8% in Q1 FY27 to 23.9% in Q2 FY27
  • PAT grew 84.4% YoY to ₹17.18 crores in Q2 FY27 and 97.9% YoY to ₹25.46 crores in H1 FY27

Source: Inve analysis of Anlon Healthcare Limited’s Q2 FY27 earnings call · to 3 Nov 2026

Compare across 5 analysed calls

Price & Snapshot

₹25.56 −0.81% · −₹0.21

Last close 17 Nov 2026 · NSE · INR · Source: Inve

Performance −82.1% 1Y

₹50₹100₹150Nov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q2 FY26 — 19 Nov 2025Q3 FY26 — 19 Feb 2026Q4 FY26 — 3 Jun 2026Q1 FY27 — 6 Aug 2026Q2 FY27 — 3 Nov 2026

1Y: ₹142.98 on 14 Nov 2025 → ₹25.56. High ₹168.61 (28 Nov 2025), low ₹13.11 (4 May 2026).

Previous close
₹25.77
Market cap
₹1.4k Cr
52-week range
₹13.11 – ₹168.61
One year
−82.97%
Price to earnings (TTM to Sept 2026)
41.00×
Return on equity (TTM to Sept 2026)
13.62%

Reported

Key financial metrics & valuation ratios

Revenue: 102 ₹ crore (+96.2% YoY) · Net profit: 17.0 ₹ crore (+88.9% YoY) · Return on equity: 13.62 % (−7.6 pts). Every row keeps its filed period and basis.

MetricValueChangeBasisPeriodNote
Revenue102 ₹ crore+96.2% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin24.0 %−2.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit17.0 ₹ crore+88.9% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity13.62 %−7.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-55.51 %−39.4 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026
(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable—Trailing twelve monthsTTM to Sept 2026
Not in the analysed materials. No older figure is substituted.

Source: Quarterly results & TTM/FY financial ratios · to Sept 2026

Customers, suppliers & partners

Customers, suppliers & partner mentions

Named customers, suppliers, and partners mentioned on recent earnings calls. Click any row to read the disclosure.

Products, transactions and disclosed impact

  • Acquisition Anlon Healthcare Limited → acquires → Apiqo Organics holding to make it a 100% wholly-owned subsidiary (by share swapping) · Stage: Approval pending · 2026-08-06

Counterparties named by Anlon Healthcare Limited

  • Anlon Healthcare Limited → acquires or invests in → Remember India (Anlon Medicos)

    Acquires / invests · Closed / completed · Q2 FY27
  • Anlon Healthcare Limited → acquires or invests in → Bizotic Lifescience and Apiqo Organics

    Acquires / invests · Announced · Q2 FY27
  • Anlon Healthcare Limited → acquires or invests in → Bizotic Lifesciences

    Acquires / invests · Announced · Q1 FY27
  • Anlon Healthcare Limited → acquires or invests in → Apiqo Organics

    Acquires / invests · Announced · Q1 FY27
  • Anlon Healthcare Limited → acquires or invests in → Remember India Health links

    Acquires / invests · Closed / completed · Q1 FY27
  • Anlon Healthcare Limited → acquires or invests in → Remember Pharma

    Acquires / invests · Closed / completed · Q4 FY26
  • Anlon Healthcare Limited → acquires or invests in → Bizotic Life Science

    Acquires / invests · Closed / completed · Q4 FY26
  • Anlon Healthcare Limited → acquires or invests in → Apiqo Organics Private Limited

    Acquires / invests · Closed / completed · Q4 FY26
  • Anlon Healthcare Limited → acquires or invests in → Apiqo and Bizotic

    Acquires / invests · Announced · Q3 FY26
  • Anlon Healthcare Limited → acquires or invests in → Bizotic Life Science

    Acquires / invests · Announced · Q3 FY26

Similar pressures reported by peers

Tailwind coverage is not available yet.
  • Petrochemical solvents and raw materials remain high since March geopolitical conflict,…

    28 other companies · Raw material cost · Q2 FY27

Mentions over time

Q4 2025 – Q3 2026

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Company Reference

Symbol
NSE:AHCL
Exchange
NSE
Currency
INR

What Anlon Healthcare Limited does

Sourced to annual report & earnings calls.

Anlon Healthcare Limited, incorporated in 2013 and based in Rajkot, Gujarat, is a research-driven chemical manufacturer of high-purity advanced pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). Its intermediates and APIs serve as key starting materials and raw materials for finished dosage formulations (tablets, capsules, syrups, ointments), and it is among the few Indian manufacturers of Loxoprofen Sodium Dihydrate, Ketoprofen and Dexketoprofen Trometamol, key APIs used for pain and inflammation. The company also offers end-to-end custom manufacturing (CDMO) services, taking molecules from process development through commercial-scale production for global innovator clients, and separately makes nutraceutical products supplied to pharmaceutical, nutraceutical, personal care and animal-health customers.

Segments

  • Active Pharmaceutical Ingredients (APIs)
  • Pharmaceutical Intermediates
  • Nutraceuticals
  • Custom Manufacturing (CDMO)
Installed manufacturing capacity
1,400-1,600 MTPA
Manufacturing blocks
2 dedicated blocks (APIs & Intermediates) at Rajkot
Capacity utilization
62.37%
Product portfolio
65 commercialized, 28 in pilot stage, 49 under lab testing
Drug Master Files (DMFs) filed
21
Global presence
15 countries
Founded 2013Headquarters Rajkot, Gujarat, IndiaEmployees 105 (FY26) Company website

How the price took the results

Moved an average of ±1.9% across the last 5 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q2 FY273 Nov 26102 17+96.2%₹24.69 → ₹25.4+2.9%
Q1 FY276 Aug 26163 8+393.9%₹14.49 → ₹14.21−1.9%
Q4 FY263 Jun 264 11−91.8%₹13.63 → ₹13.72+0.7%
Q3 FY2619 Feb 2636 5+284.6%₹121.82 → ₹118.04−3.1%
Q2 FY2619 Nov 2552 9—₹157.58 → ₹158.95+0.9%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case & results alerts for Anlon Healthcare Limited

Free account: one Inve Case, 50 concall reads/mo, 5 full ledgers, and results-day alerts.

Write why you follow Anlon Healthcare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance, and notifies you when a new call moves your thesis.

Quick Answers

Frequently asked questions on Anlon Healthcare Limited

Compiled directly from AHCL's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Anlon Healthcare Limited (AHCL) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Anlon Healthcare Limited reported revenue of ₹102 Cr, net profit of ₹17 Cr, an operating margin of 24.0%. Diluted earnings per share stood at ₹0.25.

How is Anlon Healthcare Limited (AHCL) valued today, and what growth does the stock price imply?

Anlon Healthcare Limited (AHCL) trades at ₹25.56, with a market capitalization of ₹1.4k Cr, a trailing P/E multiple of 41.00×, return on equity (ROE) of 18.28%, ROCE of 21.03%.

Did Anlon Healthcare Limited (AHCL) management keep or miss its earnings call guidance?

Across 24 management guidance targets tracked from Anlon Healthcare Limited's earnings calls, 0 were achieved, 6 missed, and 18 remain open (0% delivered among resolved targets). Sampled guidance includes Net Debt: "by third quarter of next financial year, we will be the debt-free. No bank loan for new expansion." (stated in Q2 FY26, current status: missed).

Who owns Anlon Healthcare Limited (AHCL) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 52.7%, FIIs hold 1.0%, DIIs hold 0.3%, Public shareholders hold 46.0%.

What did Anlon Healthcare Limited (AHCL) management cover on its latest concall (Q2 FY27)?

On its Q2 FY27 (Nov 2026) concall, Anlon Healthcare demonstrated strong operational growth in Q2 FY27, with consolidated revenue doubling YoY to ₹105.61 crores and H1 FY27 performance exceeding the full-year FY26 topline. EBITDA margins rebounded sharply to 23.9% from 17.8% in Q1 FY27, driven by successful price revisions to absorb elevated raw material costs. The company is actively executing a ₹130 crore greenfield expansion at Rajkot to add 1,200 MTPA capacity by Q1 FY28, while expanding into finished dosages, biologics, and medical devices. Read Anlon Healthcare Limited Q2 FY27 concall summary →